Drug Profile

EG 102

Alternative Names: EG-102

Latest Information Update: 15 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Focal segmental glomerulosclerosis
New Molecular Entity Yes

10 Oct 2024 Preclinical trials in Focal segmental glomerulosclerosis in USA (unspecified route) prior to October 2024 (Evergreen Therapeutics pipeline, October 2024)
11 Apr 2022 Shenzhen Eglin Pharmaceutical has patent protection for EG 102 (Evergreen Therapeutics pipeline, April 2022)
11 Apr 2022 EG 102 receives Orphan Drug status for Focal segmental glomerulosclerosis in China (Evergreen Therapeutics pipeline, April 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com